BTRC and leukemia: The inhibition of Janus Kinase 2 (JAK2) either by small-molecule inhibitor AG490 or by knockdown with shRNA results in an increase in β-TrCP and GSK3α/β at both the mRNA and protein level in both human leukemia Jurkat cells and human erythroleukemia HEL cells [168].